

Novagali Pharma strengthens its Executive Management by appointing Dr Mourad Amrane to the head of Medical Affairs

19 December 2007 (Evry, France) - Novagali Pharma an emerging pharmaceutical company specialized in ophthalmology announces today the appointment of Dr Mourad Amrane as Vice President of Medical Affairs. He is in charge both of the clinical product development and the medical marketing activities, which aim at defining and optimizing the product strategies.

Dr Amrane, an ophthalmologist by training, was since 2005 medical ophthalmology manager within Pfizer France where he was in charge of products intended to treat glaucoma. He began his career with hospital experience as ophthalmologist. In 1996, at the same time as this activity, he integrated the FDM Pharma company as medical doctor in charge of epidemiological studies and in 1998 was placed in charge of a phase III study. This experience will mark the beginning of eight years of activity in Clinical Research Organization which continued from 1999 with Gecem, where he managed several clinical programs of phases II, III and IV.

The appointment of Dr Mourad Amrane further reinforces the solid experience of the executive management of Novagali Pharma which was strengthened earlier this year by the appointments of Genevieve Garrigos (Communication and Human Resources) and Philippe Garcia (Finance) in April, and Sylvie Elia-Foeillet (Pharmaceutical Affairs) in June. *"We are very happy to welcome Dr Amrane who will bring us all his experience in term of clinical development and will contribute significantly to the marketing and promotion of our products"*, said Jérôme Martinez, Chairman of the Managing Board (*Directoire*) of Novagali Pharma.

About Novagali Pharma : <http://www.novagali.com>

Novagali Pharma is an emerging ophthalmic pharmaceutical company based in the *Génopôle* biocluster in Evry (France), that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb[®] and Eyeject[®], the company has developed a broad pipeline of 8 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia[®], an orphan product for treatment of vernal keratoconjunctivitis, Cationorm[®], a CE mark product for dry eye relief, and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma has 46 employees.

Press contacts

Novagali Pharma

VP RH & Communication

Geneviève Garrigos

+33 1 69 87 40 20

genevieve.garrigos@novagali.com

Euro RSCG C&O

Emilie Dhélens

+ 33 1 58 47 95 62

emilie.dhelens@eurorscg.fr